INV 88
Alternative Names: INV-88; Macrophage migration inhibitory factor inhibitor - Innovimmune Biotherapeutics; MIF inhibitor - Innovimmune BiotherapeuticsLatest Information Update: 28 Jan 2024
At a glance
- Originator Innovimmune Biotherapeutics
- Class Antidementias; Antidepressants; Antifibrotics; Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Macrophage migration-inhibitory factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Depressive disorders; Haematological malignancies; Idiopathic pulmonary fibrosis; Solid tumours
- No development reported Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
- 02 Jun 2022 Innovimmune Bioherapeutics' patent protection expires - fee related for INV 88 in USA